Cart Summary
0 item(s) ($0.00)
IJCAHPO Meetings and Weekly Webinars
Product Categories
Event Details

Event Registration - Burning Questions Featuring Ken Jeong
Tuesday, September 14, 2021
Tuesday, September 14, 2021
Exclusive virtual event hosted by IJCAHPO, sponsored by Novartis Pharmaceuticals Corporation. As part of our continued commitment to technician education on dry eye disease, please join us for Burning Questions—a live, virtual event featuring real dry eye patient Ken Jeong, alongside eye care experts and Novartis employees Dr. Whitney Hauser and Dr. Jay Mattheis.

Webinar Access Link: Registrants will receive an email containing login information for this webinar.
If you have any questions, please contact the Administrative Services Department at (800-284-3937) or e-mail
This will be your only opportunity to attend Burning Questions. RSVP today to reserve your spot for this exclusive, live event and don't forget to submit your burning question

Registration is now Closed.

Title: Novartis Presents: Burning Questions - A Live Virtual Event Featuring Ken Jeong
Date: Tuesday, September 14, 2021, 6:30 pm, Central Time (7:30 pm Eastern, 5:30 pm Mountain, 4:30 pm Pacific)
  • Ken Jeong, Real Dry Eye Patient
  • Whitney Hauser, OD, FAAO, Director, Peer Education for Novartis US Ophthalmics
  • Jay K Mattheis, MD, MSPH, FACS, Director, Peer Education for Novartis US Ophthalmics
There is no continuing education (CE) credit associated with this event.

  • Registration deadline for webinars is 2:00 PM, Central Time, the Monday prior to the webinar presentation date.
  • Once you have completed your webinar registration, you will receive an Order Confirmation at the email address on file.
  • If an Order Confirmation is not received, you have not successfully registered for the webinar.
  • A personal email address is required for registration. IJCAHPO Certification is not required to register for webinars.

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information
  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.
Click here for Full Prescribing Information.

8/21          149321

Progress %

Elapsed time:  Estimated time: